Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M

Oncology Institute, Inc.

Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
Net loss narrowed to $7.5M from $13.2M; adj EBITDA improved to $147K from -$7.8M.
FY2025 revenue $502.7M (+27.8%); net loss $60.6M vs $64.7M; adj EBITDA -$12.4M vs -$35.7M.
Added 9 new capitated contracts in CA, FL, NV covering ~260K lives; expanded Elevance, Humana, CarePlus partnerships.
Cash from operations positive $3.2M in Q4; cash balance $33.6M at year-end.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncology Institute, Inc. reported fiscal year ended December 31, 2025 results: revenue $502.7 million, net income Net loss of $60.6 million, EPS $(0.54) basic and diluted loss per share.

Period: fiscal year ended December 31, 2025
Revenue: $502.7 million
Net income: Net loss of $60.6 million
EPS: $(0.54) basic and diluted loss per share
Result: reported results

Exact text from the filing

million as of December 31, 2025 Year Ended 2025 Financial Highlights All comparisons are to the year ended December 31, 2024 unless otherwise noted • Consolidated revenue of $502.7 million, increased 27.8% • Gross profit of $76.4 million, an increase of 41.6% • Net loss of $60.6 million compared to $64.7 million • Basic and diluted loss per share of $(0.54) and

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncology Institute, Inc. reported fourth quarter ended December 31, 2025 results: revenue $142.0 million, net income Net loss of $7.5 million, EPS $(0.06) basic and diluted loss per share.

Period: fourth quarter ended December 31, 2025
Revenue: $142.0 million
Net income: Net loss of $7.5 million
EPS: $(0.06) basic and diluted loss per share
Result: reported results

Exact text from the filing

MA lives in South Florida Fourth Quarter 2025 Financial Highlights All comparisons are to the quarter ended December 31, 2024 unless otherwise noted • Consolidated revenue of $142.0 million, increased 41.6% • Gross profit of $22.7 million, an increase of 55.2% • Net loss of $7.5 million compared to $13.2 million • Basic and diluted loss per share of $(0.06) compared

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-26-000291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.